George Scangos, CEO of biotech powerhouse Biogen Idec, and David Page, director of MIT's Whitehead Institute for Biomedical Research, have made a $5.3 million handshake, the Boston Globe reports, as the two institutions plan to collaborate on early-phase development.
Last night I was a guest lecturer at an MIT class of biomedical PhD candidates. One of the professors had asked me to come and provide my take on covering biotech news, and I took it on for largely selfish reasons.
Pfizer is partnering with the Massachusetts Institute of Technology (MIT) to see if they can find new processes that will cut costs and increase efficiency, the Boston Business Journal reports.
Last summer PhRMA reported there are 19 stroke drugs in clinical trials, with GlaxoSmithKline, Pfizer and Sanofi all vying to bring a product to market. Recent history suggests many of these compounds will flunk Phase III trials, but if a robotics team at MIT has its way the failures will at least be faster and cheaper than in the past.
Scientists from Alnylam teamed with MIT researchers to develop a new nanoparticle platform with which to better deliver the genetic material to the liver. With MIT professor Robert Langer as one of its authors, the team published a paper in the journal Proceedings of the National Academy of Sciences highlighting its particles, which are inspired by the vehicles the body uses to transport cholesterol.
Memorial Sloan-Kettering Cancer Center in New York now has an extra $90 million to devote to cancer immunotherapy research.
MIT scientist and entrepreneur Robert Langer is co-founding yet another new med tech company, this time in France. Gecko Biomedical debuts with nearly $11 million in Series A financing, focused on a light-activated, biodegradable, non-toxic adhesive designed to close wounds inside the body.
As Visterra readies an influenza antibody for Phase I trials, the Gates-foundation-backed biotech announced today it's hired veterans of Mascoma and Concert Pharmaceuticals and licensed an antibody to treat the dengue virus out of the MIT lab of its co-founder, Dr. Ram Sasisekharan.
If you want to cripple cancer cells, go straight for their power source, according to researchers at MIT and the University of Toronto. The scientists have developed a delivery method for the cancer drug cisplatin that sends it straight to the energy-producing mitochondria of the offending cells.
MIT professor and biotech entrepreneur Robert Langer and colleagues have created a synthetic version of the natural high-density lipoprotein--or "good cholesterol"--for use in drug delivery to treat cardiovascular diseases such as atherosclerosis.